Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Liabilities and Shareholders Equity (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Liabilities and Shareholders Equity for 10 consecutive years, with $284.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 59.85% year-over-year to $284.7 million, compared with a TTM value of $983.8 million through Dec 2025, up 47.86%, and an annual FY2025 reading of $284.7 million, up 59.85% over the prior year.
  • Liabilities and Shareholders Equity was $284.7 million for Q4 2025 at Zevra Therapeutics, up from $270.1 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $284.7 million in Q4 2025 and bottomed at -$426000.0 in Q2 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $145.6 million, with a median of $138.9 million recorded in 2021.
  • The sharpest move saw Liabilities and Shareholders Equity tumbled 100.31% in 2022, then soared 32724.88% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $132.9 million in 2021, then fell by 13.24% to $115.3 million in 2022, then skyrocketed by 49.41% to $172.3 million in 2023, then increased by 3.37% to $178.1 million in 2024, then soared by 59.85% to $284.7 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for ZVRA at $284.7 million in Q4 2025, $270.1 million in Q3 2025, and $256.3 million in Q2 2025.